Tradestie Institutional Equity Comparison Engine

TBPH vs DSGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TBPH Overall Edge

TBPH Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Theravance Biopharma, Inc. (TBPH) driven by superior Valuation, Growth & Margin, Momentum & Technical while DSGN counters with relative strength in Options & Structure. Fundamentally, TBPH trades at 13.4x Forward P/E with 8.9% operating margin (-20.9% YoY revenue) versus DSGN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, TBPH sits in UNCLASSIFIED (16th %ile IV; Dealer Gamma Walls on Pro) against DSGN sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TBPH
TBPH 13.4x vs DSGN N/M Fwd P/E
Growth & Margin Winner TBPH
Op Margin 8.9% vs 0.0% ยท YoY -20.9% vs +0.0%
Momentum & Technical Winner TBPH
1Y +21.0% vs +40.8% ยท 52W Pos 50% vs 30%
Options & Structure Winner DSGN
UNCLASSIFIED (16th %ile IV) vs BREAKDOWN (13th %ile IV)
TBPH NASDAQ
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
1M Return +0.12%
1Y Return +21.04%
Forward P/E 13.4x
Unified AI Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
1M Return -3.59%
1Y Return +40.79%
Forward P/E N/M
Unified AI Score
49.8 / 100 HOLD
Tech 55.0 Fund 57.0 Flow 63.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TBPH +21.04% DSGN +40.79% Spread: +80.2 pp (DSGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TBPH TTM Op. Margin: 8.9% DSGN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TBPH vs DSGN. Trailing 12-month operating profitability (TBPH 8.9% vs DSGN 0.0%) and valuation multiples (TBPH 13.4x vs DSGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TBPH (9) vs DSGN (1)
Institutional Metric TBPH DSGN Criterion Row Winner
Market Capitalization Scale $884.2M $677.5M Larger Scale TBPH
Trailing P/E Ratio Valuation 16.4x N/M Lower Multiple TBPH
Forward P/E Ratio Valuation 13.4x N/M Lower Multiple TBPH
Revenue Growth (YoY) Growth -20.9% +0.0% Higher Growth DSGN
Operating Margin (TTM) Profitability 8.9% 0.0% Higher Margin TBPH
Net Profit Margin Profitability 51.6% 0.0% Higher Margin TBPH
Return on Equity (ROE) Capital Efficiency 20.9% -36.9% Higher ROE TBPH
52-Week Range Position Momentum 50% ($13โ€“$21) 30% ($7โ€“$17) Stronger Trend TBPH
Beta / 30D Volatility Risk Regime 0.48ฮฒ ยท 2% Vol 1.32ฮฒ ยท 61% Vol Lower Realized Risk TBPH
Unified Institutional Score Composite Signal 54.9 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite TBPH

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TBPH vs DSGN Buy Guide
TBPH UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live TBPH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DSGN BREAKDOWN
139d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live DSGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TBPH nor DSGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.